| Bioactivity | FAK-IN-16 (compound OXA-11) is an orally active, selective focal adhesion kinase (FAK) inhibitor with an IC50 of 1.2 pM. FAK-IN-16 inhibits FAK phosphorylation at pFAK[Y397] and pFAK[Y861]. FAK-IN-16 slows tumor growth and reduces tumor vascularity, invasion. FAK-IN-16 potentiates effects of Cisplatin (HY-17394) on tumor cell proliferation and apoptosis in vitro and anti-tumor actions in mice[1]. |
| Name | FAK-IN-16 |
| CAS | 1257994-15-2 |
| Formula | C37H49F3N7O5P |
| Molar Mass | 759.80 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ingrid Moen, et al. Anti-metastatic action of FAK inhibitor OXA-11 in combination with VEGFR-2 signaling blockade in pancreatic neuroendocrine tumors. Clin Exp Metastasis. 2015 Dec;32(8):799-817. |
FAK-IN-16
CAS: 1257994-15-2 F: C37H49F3N7O5P W: 759.80
FAK-IN-16 (compound OXA-11) is an orally active, selective focal adhesion kinase (FAK) inhibitor with an IC50 of 1.2 pM.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.